Journal
DRUG RESISTANCE UPDATES
Volume 28, Issue -, Pages 65-81Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.drup.2016.07.001
Keywords
Cancer; Chemotherapeutics; Anticancer drugs; Doxorubicin (adriamycin); Cisplatin; Drug resistance; Biomarkers
Categories
Funding
- Institute for Chemical Immunology, an NWO Gravitation project - Ministry of Education, Culture and Science of the government of the Netherlands
- Dutch Cancer Society KWF
- NWO TOP grant
- ERC Advanced grant
Ask authors/readers for more resources
Efficacy of chemotherapy in the treatment of distinct malignancies is often hampered by drug resistance arising in the tumor. Understanding the molecular basis of drug resistance and translating this knowledge into personalized treatment decisions can enhance therapeutic efficacy and even curative outcome. Over the years, multiple drug resistance mechanisms have been identified that enable tumors to cope with the damage instigated by a specific drug or group of anti-tumor agents. Here we provide an overview of the molecular pathways leading to resistance against conventional anti-cancer drugs, with emphasis on the utility of these pathways for rational selection of treatments for individual cancer patients. We further complement the review by discussing the pitfalls and difficulties in translating these findings into novel treatment strategies for cancer patients. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available